Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?

Rob Mac Sweeney,1,2 Daniel Francis McAuley1,2

Despite decades of research, no specific pharmacological therapy to treat acute lung injury (ALI) has been identified. At present, the only effective therapies act by limiting iatrogenic injury associated with positive fluid balance6 or mechanical ventilation.7 As efforts to pharmacologically modulate the complex inflammatory process which leads to alveolar injury have been unsuccessful, the focus has changed to cell-based therapy, aimed at utilising stem cells which have pleiotropic effects and which respond appropriately to local signalling molecules.

Mesenchymal stem cells (MSC) are multipotent adult stem cells with the capacity to differentiate into many different cell types, including alveolar cells. There are several mechanisms through which MSCs could potentially be used for attenuating lung injury and augmenting repair.7,8 On the basis of the currently available data, and supported by two papers,7,8 the most important therapeutic effect of exogenously administered MSCs is their localisation to the site of injury and differentiation into mature cells replacing injured cells and promoting repair. Possible further therapeutic approaches include the use of exogenous MSCs as a means of delivering gene therapy or the upregulation of endogenous MSCs via the administration of exogenously administered growth factors.9

The preclinical studies address the use of MSCs in ALI and support the need to progress to an early phase clinical trial. As MSCs reduce inflammation, a possible consequence might be reduced host defence with decreased capacity to clear infection. To test the effects of MSCs in ALI due to pneumonia, Gupta and colleagues undertook a series of studies, both in vitro and in vivo, to investigate the effects and mechanisms of MSCs in a murine model of Escherichia coli pneumonia. Intratracheally administered murine MSCs reduced lung injury and improved survival compared with controls. Although an anti-inflammatory effect was seen with MSC administration, in the form of reduced pro-inflammatory cytokine levels, reassuringly microbial clearance was increased. The antimicrobial effect was largely due to the upregulation of lipocalin 2, which acts by sequestering bacterial siderophore-iron complexes, thus limiting bacterial iron supply and contributing a bacteriostatic effect to the innate immune system.10 This adds to previous work from the same group which found another antimicrobial peptide, LL-37, also contributed to the antibacterial effect of MSCs.11

The reparative potential of MSCs was elegantly demonstrated by Curley et al in a novel model of injury and repair following ventilator-induced lung injury.7 Postinjury intravenously delivered rat MSCs, or rat MSC conditioned medium (CM), significantly decreased rodent lung injury, as measured functionally, biochemically and pathologically. In an in vitro human alveolar epithelial wound repair model, using human MSCs and human MSC CM, both MSCs and MSC CM induced greater repair compared with control. Using inhibitors to three growth factors, KGF, hepatocyte growth factor and transforming growth factor β, KGF alone was significantly associated with improved wound repair. Levels of KGF were higher in MSC CM than in fibroblast CM, suggesting that the MSCs were the source of this growth factor.

Given the repeated failure of pharmacological therapies to improve outcome in ALI, a novel approach to ALI research is welcome. Numerous other preclinical studies, ranging from cell to rodent to vivo to human ex vivo studies, have demonstrated the efficacy of MSCs when used across a spectrum of models of ALI.12 A recent double blind, randomised controlled trial of MSCs in acute myocardial infarction reported no adverse effects with this therapy and improved functional outcomes.13

However, before undertaking human clinical studies, several issues require to be addressed. First, whether it is the MSCs, their secreted products, or both, which are therapeutic in ALI is uncertain. The study by Curley and colleagues7 demonstrates that both are therapeutic, with secreted KGF appearing to be the effect mediator. These findings are consistent with data from a human ex vivo lung perfusion model of ALI induced by E coli endotoxin, where both MSCs and MSC CM were effective in improving alveolar fluid clearance.14 Consistent with the present study, KGF also appeared to be the crucial mediator of this improvement. KGF has been investigated in a range of experimental lung injury models and in one human model of ALI (ISRCTN98813895). In addition to being a potent mitogen, it has numerous effects including cellular repair, cytoprotection, alveolar fluid clearance modulation and immunomodulation.15 Potentially, KGF could provide a viable alternative to MSC therapy. A single centre, double blind, randomised controlled trial of KGF in ALI (KARE study, ISRCTN95690673) is ongoing and will further inform this issue.

Second, the antimicrobial effect of MSC therapy requires further thought. The study by Gupta et al provides reassuring data in a bacterial model of ALI. This is supported by data from a recent study (published in abstract), from the human ex vivo lung perfusion injury model induced by live E coli, where MSCs were effective in improving alveolar fluid clearance.16 The antimicrobial effect of MSC therapy in this current study in Thorax was largely due to lipocalin secreted from

1Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, Northern Ireland; 2Centre for Infection and Immunity, Queen’s University Belfast, Belfast, Northern Ireland

Correspondence to Dr Daniel F McAuley, Centre for Infection and Immunity, Queen’s University Belfast, Health Sciences Building, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland; d.f.mcauley@qub.ac.uk

Downloaded from http://thorax.bmj.com/ on June 24, 2017 - Published by group.bmj.com
Mesenchymal stem cells (MSCs), rather than MSC CM modifying resident alveolar macrophage activity. It is uncertain how much this antimicrobial effect contributed to the improvement of these injured mice and how much was due to the reparative effects of the MSCs; however, this raises the question as to whether MSCs might be more beneficial for infectious causes of ALI and a product such as KGF be more suitable for non-infectious causes. Additionally, the use of MSCs during catecholamine therapy for septic shock, a group of vasoactive agents known to augment bacterial iron handling, could potentiate their antimicrobial effect given the mechanism of action of lipocalin.

Third, the potential dose regimen remains unknown for ALI. The optimal dose and whether a single dose or multiple dosing regimen is required is unclear. Curley et al demonstrated a beneficial effect with multiple doses. The dosing regimen has varied across studies, as exemplified by these two studies. Also, similarly, the optimal route of administration is unknown; however, both intravenous and intratracheal administration has been used successfully. On balance, supported by these papers, it would seem most appropriate in an initial phase II clinical trial to administer the highest tolerated dose of MSCs intravenously in multiple doses.

Finally, in addition to their potential use during ALI, MSCs or their products could have a role in reconditioning lungs harvested for transplantation, but subsequently deemed too severely injured for use. Ex vivo perfusion of such harvested lungs can restore function to a level suitable for use, and when transplanted, these lungs are not inferior to normally transplanted lungs. The addition of MSCs, or their secreted growth factors, to this ex vivo preparation could have further reparative effects. Approximately 85% of lungs offered for donation are deemed unsuitable due to ALI occurring at the time of brain death. Any intervention which could restore function to these organs and increase transplantation rates is worthy of further investigation.

Rather than attempting to pharmacologically inhibit individual components of the highly conserved, complex homeostatic inflammatory process, MSC therapy affords a new treatment paradigm for ALI. It is time for a clinical trial to answer the questions that the studies by Gupta et al and Curley et al now compel us to ask: are MSCs a viable therapy for ALI?

Contributors RMS wrote the initial draft and DFM edited and finalised the final version.

Funding DFM is funded by the Northern Ireland Public Health Agency Research and Development Division Translational Research Group for Critical Care.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

Thorax 2012;67:1–2. doi:10.1136/thoraxjnl-2011-201309

REFERENCES


Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?

Rob Mac Sweeney and Daniel Francis McAuley

Thorax published online April 13, 2012

Updated information and services can be found at: http://thorax.bmj.com/content/early/2012/04/12/thoraxjnl-2011-201309

These include:

References
This article cites 18 articles, 3 of which you can access for free at: http://thorax.bmj.com/content/early/2012/04/12/thoraxjnl-2011-201309#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)
- Adult respiratory distress syndrome (111)
- Mechanical ventilation (158)
- Inflammation (1020)
- Drugs: infectious diseases (968)
- Mechanical ventilation (171)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/